Summit Therapeutics Announces Completion of Enrollment in Its Phase III Harmoni Trial in 2L+ Egfrm Nsclc
summit therapeutics宣佈其2L+ EGFRM NSCLC第三期Harmoni試驗招募工作已完成
Summit Therapeutics Announces Completion of Enrollment in Its Phase III Harmoni Trial in 2L+ Egfrm Nsclc
summit therapeutics宣佈其2L+ EGFRM NSCLC第三期Harmoni試驗招募工作已完成
譯文內容由第三人軟體翻譯。